Apr 20, 2020
Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
Mar 31, 2020
InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation
Feb 25, 2020
InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal
Feb 19, 2020
InDex Pharmaceuticals' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results and Supports the Strategy Going Forward
Nov 18, 2019
InDex Pharmaceuticals Presents at Redeye Life Science Day and Avanza Börsdag November 19, 2019
Oct 09, 2019
Bulletin from Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)
Aug 27, 2019
InDex Pharmaceuticals Meets Primary Endpoint in the Phase IIb Study CONDUCT with Cobitolimod in Ulcerative Colitis
Jun 26, 2019
InDex Pharmaceuticals Gets New Patent in Europe
Jun 26, 2019
InDex Pharmaceuticals Enrolls Last Patient in Phase IIb Study CONDUCT With Cobitolimod
Apr 11, 2019
InDex Pharmaceuticals Provides Status Update on the Patient Recruitment in the CONDUCT Study
Feb 20, 2019
InDex Pharmaceuticals Holding AB (publ) Year end Report 2018
Oct 19, 2018
InDex Pharmaceuticals Publishes Post-hoc Analysis of the COLLECT Study
Aug 09, 2018
InDex Pharmaceuticals Updates Timeline for Top Line Results from the CONDUCT Study to First Half of 2019
May 31, 2018
InDex Pharmaceuticals Will Participate in the Digestive Disease Week (DDW)
May 04, 2018
InDex Pharmaceuticals Develops Oral Formulation of Cobitolimod
Apr 12, 2018
InDex Pharmaceuticals Announces the Agenda for its Capital Markets Day in Stockholm on April 25, 2018
Mar 28, 2018
InDex Pharmaceuticals gets New Patent in Japan
Feb 26, 2018
InDex Pharmaceuticals Holding AB (publ) Year end Report 2017
Feb 13, 2018
InDex Pharmaceuticals Presents Mechanism of Action Data for Cobitolimod at the ECCO Congress
Dec 01, 2017
InDex Pharmaceuticals Reports New Mechanism of Action Data for Cobitolimod